Our current data suggest that, as an alternative to NSAIDs and as a novel approach for treating neuroinflammation, manipulating PGD2 signaling with, for example, DP2 receptor antagonists, could have a significant translational and multifactorial potential as a therapeutic for AD. This evidence concerns the gene HPGDS and Alzheimer disease.